Home/Biosimilar Atlas/Companies/Alvotech

Alvotech

Biosimilar developer, Iceland. 5 development products across 5 molecules: adalimumab, aflibercept, denosumab, golimumab, ustekinumab.

First approval in the Atlas: Nov 2021, Libmyris, adalimumab (EMA)
FDAproducts approved2
EMAproducts approved5
MHRAproducts approved5
PMDAproducts approved0
HCproducts approved2
CDSCOproducts approved0
EDEproducts registered0
Connections
5molecules5products4 of 7markets2candidates in trials8companies on the same molecules

About Alvotech

Alvotech, based in Iceland, develops biosimilars and licenses every one of them to partners rather than selling itself. Its adalimumab is sold by Teva in the United States and Stada in Europe; its ustekinumab by Teva, Stada and JAMP; its denosumab by Stada and Dr. Reddy's; its aflibercept by Stada and Advanz; and its golimumab, the first approved outside India, by Advanz and Stada. Five molecules are approved in Europe and two in the United States.

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AdalimumabSimlandi / Hukyndra / Libmyris AVT02Feb 2024Nov 2021MHRA·Jan 2022··4/7
AfliberceptAfiveg / Mynzepli AVT06·Aug 2025MHRA····2/7
DenosumabZvogra / Kefdensis / Xbonzy / Acvybra AVT03·Nov 2025MHRA····2/7
GolimumabGobivaz / Gotenfia AVT05·Nov 2025MHRA····2/7
UstekinumabSelarsdi / Uzpruvo / Usgena AVT04Apr 2024Jan 2024MHRA·Nov 2023··4/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists fourteen comparative trials sponsored by Alvotech for six molecules: adalimumab, aflibercept, denosumab, golimumab, ustekinumab, vedolizumab. Candidates without an approval yet in the seven markets: AVT16, AVT29.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
AdalimumabAVT02AlvotechHumiraPhase 3Comparative efficacyCompletedFeb 2019Dec 2019Simlandi / Hukyndra / LibmyrisNCT03849404
AdalimumabAVT02AlvotechHumiraPhase 3Comparative efficacyCompletedJun 2020May 2021Simlandi / Hukyndra / LibmyrisNCT04453137
AdalimumabAVT02AlvotechHumiraPhase 1Comparative PKCompletedMar 2019Feb 2020Simlandi / Hukyndra / LibmyrisNCT03849313
AdalimumabAVT02AlvotechHumiraPhase 1Comparative PKCompletedMay 2018Aug 2018Simlandi / Hukyndra / LibmyrisNCT03579823
AfliberceptAVT29AlvotechEyleaPhase 3Comparative efficacyRecruitingApr 2026Jul 2027no approval in the seven marketsNCT07489131
AfliberceptAVT06AlvotechEyleaPhase 3Comparative efficacyCompletedJun 2022Nov 2023Afiveg / MynzepliNCT05155293
DenosumabAVT03AlvotechProliaPhase 3Comparative efficacyCompletedAug 2022May 2024Zvogra / Kefdensis / Xbonzy / AcvybraNCT05395091
DenosumabAVT03AlvotechXgevaPhase 1Comparative PKCompletedJul 2023Apr 2024Zvogra / Kefdensis / Xbonzy / AcvybraNCT05876949
DenosumabAVT03AlvotechProliaPhase 1Comparative PKCompletedJun 2022Oct 2023Zvogra / Kefdensis / Xbonzy / AcvybraNCT05126784
GolimumabAVT05AlvotechSimponiPhase 1Comparative PKCompletedDec 2022Oct 2023Gobivaz / GotenfiaNCT05632211
GolimumabAVT05AlvotechSimponiPhase 3Comparative efficacyCompletedMar 2023Mar 2024Gobivaz / GotenfiaNCT05842213
UstekinumabAVT04AlvotechStelaraPhase 3Comparative efficacyCompletedJun 2021Dec 2021Selarsdi / Uzpruvo / UsgenaNCT04930042
UstekinumabAVT04AlvotechStelaraPhase 1Comparative PKCompletedMay 2021Mar 2022Selarsdi / Uzpruvo / UsgenaNCT04744363
VedolizumabAVT16AlvotechEntyvioPhase 3Comparative efficacyTerminatedSep 2024Nov 2025no approval in the seven marketsNCT06570772

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Alvotech, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

CelltrionFour shared molecules: adalimumab, aflibercept, denosumab, ustekinumab10 molecules in its portfolioFuji PharmaFour shared molecules: aflibercept, denosumab, golimumab, ustekinumab5 molecules in its portfolioReliance Life SciencesFour shared molecules: adalimumab, denosumab, golimumab, ustekinumab14 molecules in its portfolioSamsung BioepisFour shared molecules: adalimumab, aflibercept, denosumab, ustekinumab10 molecules in its portfolioAmgenThree shared molecules: adalimumab, aflibercept, ustekinumab8 molecules in its portfolioBiocon BiologicsThree shared molecules: aflibercept, denosumab, ustekinumab9 molecules in its portfolioSandozThree shared molecules: adalimumab, aflibercept, denosumab10 molecules in its portfolioApotexTwo shared molecules: aflibercept, denosumab3 molecules in its portfolio

Chronology

Compare Alvotech with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.